Majewska Paulina, Ioannidis Stefanos, Raza Muhammad Hasan, Tanna Nikhil, Bulbeck Helen, Williams Mathew
School of Medicine, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.
Oncology Department, Charing Cross Hospital, Fulham Palace Rd, London, W6 8RF, UK.
CNS Oncol. 2017 Oct;6(4):307-313. doi: 10.2217/cns-2017-0001. Epub 2017 Oct 9.
Glioblastoma is the commonest malignant brain tumor in adults. Most patients develop progressive disease before they die. However, survival after developing progressive disease is infrequently reported. We identified patients with histologically proven disease who were treated with concurrent chemoradiotherapy during 2006-2013. We analyzed overall survival (OS), progression-free survival and postprogression survival (PPS) in relation to age, O6-methylguanine-DNA methyltransferase promoter methylation and extent of surgical resection. We identified 166 patients. Median survival was 13.5 months; 2-year OS was 21.7%. Median progression-free survival and PPS were 7.03 and 4.53 months, respectively. Age and extent of surgical resection were correlated with OS. Only the extent of surgical resection was associated with PPS. Our work suggests that the established prognostic factors for glioblastoma do not appear to help predict PPS.
胶质母细胞瘤是成人中最常见的恶性脑肿瘤。大多数患者在死亡前病情会逐渐进展。然而，关于病情进展后的生存率报道较少。我们纳入了2006年至2013年间接受同步放化疗且组织学确诊的患者。我们分析了总生存期（OS）、无进展生存期和进展后生存期（PPS）与年龄、O6-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化以及手术切除范围的关系。我们共纳入了166例患者。中位生存期为13.5个月；2年总生存率为21.7%。中位无进展生存期和进展后生存期分别为7.03个月和4.53个月。年龄和手术切除范围与总生存期相关。仅手术切除范围与进展后生存期相关。我们的研究表明，已确立的胶质母细胞瘤预后因素似乎无助于预测进展后生存期。
